<DOC>
	<DOC>NCT01743482</DOC>
	<brief_summary>This is an open label, single arm, single center, phase 2 study with the use of the antiangiogenic multikinase inhibitor pazopanib in a population of patients with germ cell tumors who are not cured following first or subsequent chemotherapy lines for metastatic disease, followed by eventual surgery.</brief_summary>
	<brief_title>Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors</brief_title>
	<detailed_description />
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
	<criteria>Male gender. Confirmation of GCT histology based on pathologic review at Fondazione INT Milan. Unequivocal progression of measurable disease. A minimum of 2 and a maximum of 3 platinumbased chemotherapy lines for metastatic disease. Firstline therapy should consist of at least 3 cycles of cisplatinbased chemotherapy. Prior single, tandem or triple highdose chemotherapy course given as frontline or salvage therapy is allowed. Failure to meet any of the above inclusion criteria. Concurrent treatment with other cytotoxic drugs or targeted therapies. Prior radiation therapy within 14 days of trial start.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Testicular Cancer</keyword>
	<keyword>Germ Cell Tumors</keyword>
	<keyword>Salvage Therapy</keyword>
	<keyword>Pazopanib</keyword>
</DOC>